What is Protagenic Therapeutics Inc's earnings per share (EPS)?

Protagenic Therapeutics Inc (PTIX) reported diluted earnings per share of $0.59 for fiscal year 2026. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Protagenic Therapeutics Inc Financials

PTIX

FY2026 annual

Revenue $0 YoY not available

Net Income $1.4M YoY not available

EPS (Diluted) $0.59 YoY not available

Free Cash Flow -$2.8M YoY not available

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE March

Protagenic Therapeutics Inc (PTIX) reported $0 in revenue for fiscal year 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PTIX FY2026 2026-08-19

External financing is rebuilding liquidity while reported profit remains disconnected from operating cash generation.

FY2026 reported net income of $1.4M even as operating income was -$4.5M; that gap means the bottom line was not produced by the operating engine. Because operating cash flow was -$2.8M while financing cash flow supplied $3.9M, liquidity recovery depended on funding rather than internally generated cash.

The balance sheet moved from negative equity of -$3.3M in FY2024 to positive equity of $2.6M in FY2026, restoring a capital cushion rather than merely changing an accounting ratio. Cash of $1.5M exceeded total liabilities of $1.0M in FY2026, but that cushion must be read alongside ongoing operating cash use.

R&D spending of $902K exceeded SG&A of $332K, so the expense base was weighted toward development rather than administration. Free cash flow of -$2.8M alongside only $3K of capital expenditures indicates the cash requirement was primarily operating spend, not asset-building.

Financial Health Signals

Financial health score not available

Protagenic Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-4.61

Protagenic Therapeutics Inc scores -4.61, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.5M) relative to total liabilities ($1.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

Protagenic Therapeutics Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

$2.05used

For every $1 of reported earnings, Protagenic Therapeutics Inc used $2.05 of operating cash (-$2.8M OCF vs $1.4M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Interest Coverage At Risk

N/A

Protagenic Therapeutics Inc reported an operating loss of $4.5M against $1.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Protagenic Therapeutics Inc generated $0 in revenue in fiscal year 2026.

EBITDA

-$4.5M

Protagenic Therapeutics Inc's EBITDA was -$4.5M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

Net Income

$1.4M

Protagenic Therapeutics Inc reported $1.4M in net income in fiscal year 2026.

EPS (Diluted)

$0.59

Protagenic Therapeutics Inc earned $0.59 per diluted share (EPS) in fiscal year 2026.

Cash & Balance Sheet

Free Cash Flow

-$2.8M

Protagenic Therapeutics Inc recorded an outflow of $2.8M in free cash flow in fiscal year 2026, representing a cash shortfall after capex.

Cash & Debt

$1.5M

5Y CAGR+17.6%

10Y CAGR+84.3%

Protagenic Therapeutics Inc held $1.5M in cash as of fiscal year 2026; long-term debt is not reported for that period.

Shares Outstanding

Protagenic Therapeutics Inc had 2M shares outstanding in fiscal year 2026.

Dividends Per Share

Not reported for fiscal year 2026.

Margins & Returns

Return on Equity

52.2%

Protagenic Therapeutics Inc's ROE was 52.2% in fiscal year 2026, measuring profit generated per dollar of shareholder equity.

Gross Margin

Not reported for fiscal year 2026.

Operating Margin

Not reported for fiscal year 2026.

Net Margin

Not reported for fiscal year 2026.

Capital Allocation

R&D Spending

$902K

5Y CAGR+5.2%

Protagenic Therapeutics Inc invested $902K in research and development in fiscal year 2026.

Capital Expenditures

$3K

Protagenic Therapeutics Inc invested $3K in capex in fiscal year 2026, funding long-term assets and infrastructure.

Share Buybacks

Not reported for fiscal year 2026.

PTIX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

PTIX annual income statement

Metric	TTM	FY26	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Revenue	N/A	$0	$0	$0	$0	$0	$0	N/A	N/A	N/A	$0	$0	$0
R&D Expenses	N/A	$902K	$3.8M+25.5%	$3.1M+92.8%	$1.6M+39.8%	$1.1M+62.4%	$700K-13.4%	$808K-8.3%	$881K+22.8%	$717K+71.7%	$418K	N/A	N/A
SG&A Expenses	N/A	$332K	$1.8M+45.7%	$1.2M-38.7%	$2.0M-34.5%	$3.0M+62.2%	$1.9M+44.9%	$1.3M-10.8%	$1.4M-13.0%	$1.6M+16.7%	$1.4M	N/A	$101K
Operating Income	N/A	-$4.5M	-$5.7M-25.9%	-$4.5M-27.2%	-$3.6M+14.1%	-$4.1M-62.3%	-$2.6M-22.3%	-$2.1M+9.9%	-$2.3M+2.2%	-$2.4M-5.9%	-$2.2M	N/A	N/A
Interest Expense	N/A	-$1.5M	-$1.0M-1065.2%	$108K-21.7%	$137K-72.3%	$497K+101.9%	$246K	N/A	N/A	N/A	$7K-37.6%	$11K+282.4%	$3K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Net Income	N/A	$1.4M	-$5.5M-10.5%	-$5.0M-40.6%	-$3.6M+21.4%	-$4.5M-77.5%	-$2.5M-45.6%	-$1.8M+31.5%	-$2.6M-13.2%	-$2.3M+0.7%	-$2.3M	N/A	N/A
EPS (Diluted)	—	$0.59	-$1.13	-$1.15-40.2%	-$0.82	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0.00

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25
Revenue	N/A	N/A	N/A	N/A	$0	$0	N/A	$0
R&D Expenses	$110K	N/A	$154K-43.7%	$273K-30.7%	$394K	N/A	$135K+693.3%	$17K
SG&A Expenses	$98K	N/A	$155K-3.2%	$160K+219.3%	$50K	N/A	$50K+125.6%	$22K
Operating Income	-$961K	N/A	-$925K+16.9%	-$1.1M+7.8%	-$1.2M	N/A	-$401K-13.0%	-$355K
Interest Expense	$11K	N/A	$24K-30.6%	$34K+114.4%	-$239K	N/A	-$449K-88.0%	-$239K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$3K
Net Income	-$964K	N/A	$2.2M+354.3%	-$869K+82.8%	-$5.1M	N/A	-$850K-46.0%	-$582K
EPS (Diluted)	-$0.53	N/A	$1.14+342.6%	-$0.47	-$1.37	-$2.75	-$0.16	-$0.11

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

TTM is the trailing twelve months, Q2 FY2026 through Q1 FY2027, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

No annual filing on record for: FY2025.

PTIX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

PTIX annual balance sheet

Metric	FY26	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Total Assets	$3.7M	$2.0M-54.8%	$4.3M-46.2%	$8.0M-27.3%	$11.1M+1157.9%	$879K+4.4%	$842K+20.9%	$697K-60.9%	$1.8M-43.7%	$3.2M+28278.3%	$11K-58.5%	$27K
Current Assets	$1.5M	$1.9M-55.2%	$4.2M-47.7%	$8.0M-27.3%	$11.1M+1157.9%	$879K+4.4%	$842K+20.9%	$696K-60.9%	$1.8M-43.7%	$3.2M+94450.3%	$3K-85.3%	$23K
Cash & Equivalents	$1.5M	$80K-93.8%	$1.3M+498.5%	$215K-60.2%	$541K-19.4%	$671K-16.0%	$799K+120.3%	$362K-9.3%	$400K-87.1%	$3.1M+92643.0%	$3K-85.3%	$23K
Total Liabilities	$1.0M	$5.3M+704.9%	$655K-41.5%	$1.1M+0.2%	$1.1M-44.9%	$2.0M+37.4%	$1.5M+62.7%	$908K+61.6%	$562K-18.0%	$685K+1.0%	$678K+357.6%	$148K
Current Liabilities	$1.0M	$943K+43.9%	$655K-41.5%	$1.1M+40.1%	$800K+22.0%	$655K-45.3%	$1.2M+31.9%	$908K+61.6%	$562K-18.0%	$685K+1.0%	$678K+357.6%	$148K
Total Equity	$2.6M	-$3.3M-190.5%	$3.7M-47.0%	$6.9M-30.4%	$9.9M+964.7%	-$1.1M-81.2%	-$634K-200.8%	-$211K-117.3%	$1.2M-50.8%	$2.5M+471.3%	-$667K-449.8%	-$121K
Retained Earnings	-$4.0M	-$36.3M-18.0%	-$30.8M-19.4%	-$25.8M-16.0%	-$22.2M-25.6%	-$17.7M-16.8%	-$15.2M-13.1%	-$13.4M-23.6%	-$10.8M-26.3%	-$8.6M-36.1%	-$6.3M-19.4%	-$5.3M

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25
Total Assets	$2.8M-23.4%	$3.7M-17.6%	$4.4M-11.4%	$5.0M-22.9%	$6.5M+7182.5%	$89K-95.4%	$2.0M+29.7%	$1.5M
Current Assets	$710K-54.0%	$1.5M-32.9%	$2.3M-19.6%	$2.9M-34.0%	$4.3M+4761.2%	$89K-95.3%	$1.9M+32.3%	$1.4M
Cash & Equivalents	$566K-62.5%	$1.5M-31.8%	$2.2M-18.7%	$2.7M-33.5%	$4.1M+28089.3%	$15K-81.7%	$80K+11.4%	$71K
Inventory	N/A	N/A	$1K-0.1%	$1K-1.8%	$1K+5.5%	$1K	N/A	N/A
Total Liabilities	$1.1M+4.0%	$1.0M-84.9%	$6.8M-29.7%	$9.7M-7.3%	$10.5M+107.5%	$5.0M-4.4%	$5.3M+32.5%	$4.0M
Current Liabilities	$1.1M+4.0%	$1.0M-84.9%	$6.8M-29.7%	$9.7M-7.3%	$10.5M+107.5%	$5.0M+434.8%	$943K+19.4%	$789K
Total Equity	$1.7M-34.2%	$2.6M+209.5%	-$2.4M+49.1%	-$4.7M-18.3%	-$4.0M+19.8%	-$5.0M-49.3%	-$3.3M-34.3%	-$2.5M
Retained Earnings	-$5.0M-23.9%	-$4.0M+55.8%	-$9.1M+19.5%	-$11.3M-8.3%	-$10.5M-93.7%	-$5.4M+85.1%	-$36.3M-4.5%	-$34.7M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

No annual filing on record for: FY2025.

PTIX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

PTIX annual cash flow statement

Metric	TTM	FY26	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Operating Cash Flow	-$2.0M	-$2.8M	-$4.2M-13.8%	-$3.7M-85.8%	-$2.0M+28.8%	-$2.8M-107.5%	-$1.3M-176.4%	-$488K+54.4%	-$1.1M+22.4%	-$1.4M-21.0%	-$1.1M	N/A	N/A
Capital Expenditures	N/A	$3K	N/A	$150K+8197.8%	$2K	N/A	N/A	N/A	N/A	N/A	N/A	$2K+79.1%	$1K
Free Cash Flow	N/A	-$2.8M	N/A	-$3.9M-93.1%	-$2.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$630K	$2.8M-41.3%	$4.8M+199.0%	$1.6M+116.1%	-$9.9M	N/A	$250K-76.1%	$1.0M+181.3%	-$1.3M	N/A	N/A	N/A
Financing Cash Flow	N/A	$3.9M	$2.0M	N/A	N/A	$12.6M+928.1%	$1.2M+82.6%	$670K	N/A	N/A	$4.3M	N/A	N/A

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25
Operating Cash Flow	-$944K-455.6%	$266K+152.1%	-$510K+37.2%	-$812K+53.7%	-$1.8M	N/A	-$820K-341.6%	-$186K
Investing Cash Flow	N/A	-$313K	$0	$0-100.0%	$943K	N/A	$0	$0
Financing Cash Flow	N/A	-$534K-26694800.0%	-$2+100.0%	-$599K-112.0%	$5.0M+4783.8%	$103K-93.6%	$1.6M+405.4%	$317K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

No annual filing on record for: FY2025.

PTIX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

PTIX annual financial ratios

Metric	FY26	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Return on Equity	52.2%	N/A	-136.3%-84.9pp	-51.4%-5.9pp	-45.5%	N/A	N/A	N/A	-185.3%-93.4pp	-91.9%	N/A	N/A
Return on Assets	37.5%	-282.5%-166.8pp	-115.7%-71.4pp	-44.2%-3.4pp	-40.9%+249.0pp	-289.9%-82.0pp	-207.9%+159.1pp	-367.0%-240.1pp	-126.9%-54.9pp	-72.0%	N/A	N/A
Current Ratio	1.50	2.00-4.4x	6.41-0.8x	7.18-6.7x	13.83+12.5x	1.34+0.6x	0.70-0.1x	0.77-2.4x	3.17-1.4x	4.62+4.6x	0.00-0.1x	0.15
Debt-to-Equity	0.39	N/A	0.180.0x	0.160.0x	0.11	N/A	N/A	N/A	0.46+0.2x	0.28	N/A	N/A

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25
Return on Equity	-55.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-34.5%	N/A	49.9%+67.3pp	-17.4%+60.6pp	-78.0%	N/A	-43.5%-4.9pp	-38.6%
Current Ratio	0.66-0.8x	1.50+1.2x	0.340.0x	0.29-0.1x	0.41+0.4x	0.02-2.0x	2.00+0.2x	1.80
Debt-to-Equity	0.62+0.2x	0.39	N/A	N/A	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

No annual filing on record for: FY2025.

Similar Companies

Gt Biopharma Inc GTBP

$12.7M

Salarius Pharmaceuticals Inc SLRX

$4.9M

Enveric Biosciences Inc ENVB

$6.4M

Indaptus Therapeutics Inc INDP

$171.9M

Scisparc SPRC

$3.8M

Where Protagenic Therapeutics Inc Ranks

Frequently Asked Questions

What is Protagenic Therapeutics Inc's annual revenue?

Protagenic Therapeutics Inc (PTIX) reported $0 in total revenue for fiscal year 2026. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Protagenic Therapeutics Inc profitable?

Yes, Protagenic Therapeutics Inc (PTIX) reported a net income of $1.4M in fiscal year 2026.

What is Protagenic Therapeutics Inc's EBITDA?

Protagenic Therapeutics Inc (PTIX) had EBITDA of -$4.5M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is Protagenic Therapeutics Inc's return on equity (ROE)?

Protagenic Therapeutics Inc (PTIX) has a return on equity of 52.2% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Protagenic Therapeutics Inc's free cash flow?

Protagenic Therapeutics Inc (PTIX) recorded an outflow of $2.8M in free cash flow during fiscal year 2026. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Protagenic Therapeutics Inc's operating cash flow?

Protagenic Therapeutics Inc (PTIX) recorded an outflow of $2.8M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are Protagenic Therapeutics Inc's total assets?

Protagenic Therapeutics Inc (PTIX) had $3.7M in total assets as of fiscal year 2026, including both current and long-term assets.

What are Protagenic Therapeutics Inc's capital expenditures?

Protagenic Therapeutics Inc (PTIX) invested $3K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Protagenic Therapeutics Inc spend on research and development?

Protagenic Therapeutics Inc (PTIX) invested $902K in research and development during fiscal year 2026.

How many shares does Protagenic Therapeutics Inc have outstanding?

Protagenic Therapeutics Inc (PTIX) had 2M shares outstanding as of fiscal year 2026.

What is Protagenic Therapeutics Inc's current ratio?

Protagenic Therapeutics Inc (PTIX) had a current ratio of 1.50 as of fiscal year 2026, which is considered adequate.

What is Protagenic Therapeutics Inc's debt-to-equity ratio?

Protagenic Therapeutics Inc (PTIX) had a debt-to-equity ratio of 0.39 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Protagenic Therapeutics Inc's return on assets (ROA)?

Protagenic Therapeutics Inc (PTIX) had a return on assets of 37.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Protagenic Therapeutics Inc's cash runway?

Based on fiscal year 2026 data, Protagenic Therapeutics Inc (PTIX) had $1.5M in cash against an annual operating cash burn of $2.8M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Protagenic Therapeutics Inc's Altman Z-Score?

Protagenic Therapeutics Inc (PTIX) has an Altman Z-Score of -4.61, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Protagenic Therapeutics Inc's Piotroski F-Score?

Protagenic Therapeutics Inc (PTIX) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Protagenic Therapeutics Inc's earnings high quality?

For every $1 of reported earnings, Protagenic Therapeutics Inc (PTIX) used $2.05 of operating cash (-$2.8M OCF vs $1.4M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Protagenic Therapeutics Inc cover its interest payments?

Protagenic Therapeutics Inc (PTIX) reported an operating loss of $4.5M against $1.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.